Boston Scientific Corporation

Boston Scientific Corporation

BSX-PA

$122.18

Updated: 24/09/2026, 13:15:20

Market Cap
$175.45B
Sector
Healthcare
Industry
Medical - Devices
Country
US

No historical data available

Company Profile

Boston Scientific Corporation designs, produces, and distributes medical devices globally for a broad spectrum of interventional medical fields. The company's operations are structured across three primary segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Its MedSurg portfolio offers solutions for diagnosing and managing conditions affecting the gastrointestinal and pulmonary systems, as well as addressing urological and pelvic health issues. Within its Rhythm and Neuro segment, Boston Scientific's cardiac rhythm management offerings include implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) defibrillators, alongside pacemakers and CRT pacemakers, all supported by remote patient monitoring technologies. The company also provides advanced electrophysiology tools for diagnosing and treating heart rhythm disturbances, such as 3-D cardiac mapping and navigation systems, various ablation and diagnostic catheters, intracardiac ultrasound catheters, and associated delivery systems and accessories. Furthermore, in the field of neuromodulation, it offers spinal cord stimulators for chronic pain management, indirect decompression systems, and deep brain stimulation systems for neurological disorders. The Cardiovascular segment encompasses interventional cardiology products, including drug-eluting stents for coronary artery disease, devices for percutaneous coronary interventions (PCI) addressing atherosclerosis, and sophisticated diagnostic tools such as intravascular ultrasound (IVUS) imaging catheters and fractional flow reserve (FFR) devices, utilized in coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. For peripheral vascular conditions, the company supplies stents, balloon catheters, wires, and atherectomy systems to manage arterial diseases, alongside thrombectomy and acoustic pulse thrombolysis systems, wires, and stents for treating venous conditions. Additionally, Boston Scientific provides a suite of oncology solutions, including peripheral embolization devices, radioactive microspheres, various ablation systems (thermal and cryotherapy), and micro-catheters and drainage catheters for cancer treatment. Established in 1979, the company maintains its corporate headquarters in Marlborough, Massachusetts.

USD
NYSE
CEO: Michael F. Mahoney
Employees: 45,000
https://www.bostonscientific.com
Asset Summaries
Latest generated summaries for BSX-PA

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for BSX-PA.
Share price
$122.18
Market cap
$175.45B
Exchange
NYSE
Currency
USD
CEO
Michael F. Mahoney
Employees
45,000
IPO date
22/05/2020
Beta
0.797325
Last dividend
$0.00
Day range
$119.70 – $123.27
52-week range
$97.37 – $129.12
1-day performance
2.37%
1-year performance
25.48%
Current drawdown (1Y)
-5.37%
CIK
0000885725
CUSIP
101137206
ISIN
US1011372067
Created
07/12/2025, 03:07:36
Last update
24/09/2026, 13:15:20

Track Boston Scientific Corporation with an AI analyst

See which prediction-market events move BSX-PA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to BSX-PA from your Railway `news_articles` table.

No news found for this symbol.